Therefore, CXCL16 can be another target for anti-angiogenic therapy in advanced thyroid cancer, and patients with higher CXCL16 expression might be selected for challenge targeting CXCL16 as a precision medicine approach. Here, CXCL16 is linked to thyroid cancer.